ANDRADE, LUIS E.C.
Future perspective for diagnosis in autoimmune diseases
Academia Brasileira de Ciências
Rio de Janeiro, Brasil

Available in: http://www.redalyc.org/articulo.oa?id=32713479004
Future perspective for diagnosis in autoimmune diseases

LUIZ E.C. ANDRADE
Divisão de Reumatologia, Universidade Federal de São Paulo, Escola de Medicina, Rua Botucatu, 740
04023-062 São Paulo, SP, Brasil

Manuscript received on July 16, 2008; accepted for publication on September 3, 2009;
presented by Luiz R. Travassos

ABSTRACT

Human beings have taken successive approaches for the understanding and management of diseases. Initially brewed in supernatural concepts and mystical procedures, a vigorous scientific approach has emerged on the grounds of fundamental disciplines such as anatomy, microbiology, biochemistry, physiology, immunology, pathology, and pharmacology. The resulting integrated knowledge contributed to the current classification of diseases and the way Medicine is carried out today. Despite considerable progress, this approach is rather insufficient when it comes to systemic inflammatory conditions, such as systemic lupus erythematosus, that covers clinical conditions ranging from mild pauci-symptomatic diseases to rapidly fatal conditions. The treatment for such conditions is often insufficient and novel approaches are needed for further progress in these areas of Medicine. A recent breakthrough has been achieved with respect to chronic auto-inflammatory syndromes, in which molecular dissection of underlying gene defects has provided directions for target-oriented therapy. Such approach may be amenable to application in systemic auto-immune diseases with the comprehension that such conditions may be the consequence of interaction of specific environmental stimuli and an array of several and interconnected gene polymorphisms. On the bulk of this transformation, the application of principles of pharmacogenetics may lead the way towards a progressively stronger personalized Medicine.

Key words: autoimmunity, pharmacogenetics, gene polymorphism, auto-inflammatory diseases, systemic lupus erythematosus, rheumatoid arthritis.

HISTORICAL PERSPECTIVE IN DIAGNOSIS PARADIGM

Since ancient times, human beings have struggled to provide help to those suffering from the diverse illnesses that affect mankind and other living beings. Primitive paradigms were mainly based on instinct, mysticism and supernatural approaches. Dance rituals and magic medicines were the answer that those early professionals provided to the sufferers. With the advent of the early founders of the contemporary medical science in the Mediterranean area, a rational, observational and ethical approach was progressively established. Accordingly, the diagnostic and therapeutic approaches were then modified towards more effective procedures including recommendations related to lifestyle and hygiene. However, still at those early times the prevalent theories for health and disease were largely based on beliefs, such as the miasmas and circulating humors (blood, phlegm, black and yellow bile). Therapeutic interventions included baths at special temperatures, boiling oil, ointments, bloodletting, suction cups and so on (Lyons and Petruccelli 1978).

With the advent of Renascence and the rise of the contemporary scientific system, as we know it, different fields in natural sciences started to consider
and other scientific fields contributed to the building of a new body of knowledge that progressively allowed the conception of novel medical paradigms that gradually would replace the old ones. Miasmas and circulating humors were not appropriate to the facts brought up by objective investigations in microbiology, anatomy, physiology, and the nascent clinical chemistry. The new concepts would re-shape the established nosology (disease classification system). The art of clinical examination would also change with the aim of providing clues that would guide physicians in classifying their patients according to the new nosologic classification system. Academic clinical practice would feed back this emerging nosologic classification system and vice-versa. In due time, patients were diagnosed in a classification system that included conditions such as bacterial pneumonia, left heart failure, acute hepatitis, diabetes mellitus, gouty arthritis, and so on.

It is common practice that the application of novel paradigms into practical activities lags behind the scientific advance pace. In fact, for a considerable period of time, many of the involved professionals are bound to reject the novel ideas or to under-estimate the magnitude of the coming changes. To illustrate this point, let us suppose that a regular physician from the 17th century was to be confronted with a medical assessment of a fiction patient as of today (Table I). We can easily expect that this renascence mind would be confused with mixed feelings of wonder and suspicion.

NOSOLOGIC CLASSIFICATION SYSTEM AS A FUNCTION OF SCIENTIFIC AND TECHNOLOGICAL PROGRESS

Scientific paradigms, systematic classifications of phenomena, and technology operate in an interactive mode in which each one of these three elements influences the progress of the other two (Fig. 1). Advances occurring in any of these three elements are expected to influence the two other elements. New methodological tools allow a closer look at the natural phenomena, which may contribute to improve the classification of the system and eventually confirm or challenge the established scientific paradigm. Novel scientific paradigms push the development of classification systems based on these new discoveries.

CRITICAL APPRAISAL OF THE CURRENT NOSOLOGY OF SYSTEMIC RHEUMATIC DISEASES

The current nosologic classification of systemic rheumatic diseases has emerged in the middle of the 20th century. During the first decades of the last century, the strong influence of Paul Erlich has pushed the scientific community towards the concept of “horror autotoxicus”, which was erroneously understood as the impossibility of the immune system to recognize self constituents. Systematic experimentation progressively disclosed, however, consistent evidence that, under certain circumstances, the immune system may set up a vigorous response against self tissues and organs. Some of these seminal experiments included the immunization of rabbits with thyroid tissue that elicited auto-reactive T lymphocytes and the destruction of the thyroid gland by an intense inflammatory infiltrate. In addition, the disease could be transferred to healthy animals by inoculation of lymphocytes from the immunized rabbits (Rose 1988, Doniach and Roitt 1988).

As a hint on how intense was the dispute in this field, one can evoke the episode in which the American hematologist William Harrington self injected plasma from a patient with putative immunologic thrombocytopenic purpura. After a few hours, the platelet count started falling down reaching a nadir of 7,000/mm³ coincident with an episode of generalized tonic-clonic convulsion. Fortunately, the devoted researcher recovered with no major sequel (Harrington et al. 1951).
TABLE I

Fiction patient presented to a physician at the middle age era.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic blood pressure</td>
<td>150 × 95 mmHg</td>
</tr>
<tr>
<td>Blood hemoglobin</td>
<td>9.5 g/dL</td>
</tr>
<tr>
<td>Blood lymphocyte count</td>
<td>340/mm³</td>
</tr>
<tr>
<td>Serum gamma-glutamyl transferase</td>
<td>24 U/L</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>93 mg/dL</td>
</tr>
<tr>
<td>Estimated systolic pressure in pulmonary artery</td>
<td>75 mmHg</td>
</tr>
<tr>
<td>Capillary ectasia and deletion at the nailfold</td>
<td></td>
</tr>
<tr>
<td>Antinuclear antibody 1:640 with coarse speckled nuclear pattern</td>
<td></td>
</tr>
<tr>
<td>Anti-RNP antibodies</td>
<td>1/10,240</td>
</tr>
<tr>
<td>High-resolution thorax tomography</td>
<td>ground-glass images in lung bases</td>
</tr>
</tbody>
</table>

and the LE cell phenomenon (Hargraves et al. 1948). These two pioneer autoantibodies set the road for a vigorous research field that would flourish for the whole 20th century (Tan 1997, Strassburg and Manns 2002, Sherer et al. 2004). The steady progress in the demonstration of a series of clinically relevant autoantibodies helped pave the way for the nosologic classification system for the new family of diseases, the so-called autoimmune diseases (Chan and Andrade 1992, Tan and Chan 1993, Dellavance et al. 2005).

Nowadays, the concept of autoimmunity is well established (Schwartz 1993). Diseases with widespread involvement are classified as non-organ specific autoimmune diseases. Examples of these include systemic lupus erythematosus (SLE), systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, and Sjögren’s syndrome. Those with a more restricted organ involvement are designated organ-specific autoimmune diseases. Examples of these are autoimmune thyroiditis, pemphigus vulgaris, myasthenia gravis, autoimmune hepatitis, and chronic biliary cirrhosis. Although this classification system has provided a reasonable framework to differentiate and manage these patients, it is not without flaws. In fact the extent to which a given disease is restricted to a certain organ is quite variable and many organ-specific autoimmune conditions present various degrees of systemic involvement. We can take autoimmune hepatitis type I as an example, in which skin and joint involvement is quite frequent (Manns and Vogel 2006), syndrome, in which many patients show evidence of restricted involvement of salivary and lachrymal exocrine glands (Fox 2005, Barcellos et al. 2007). Rheumatoid arthritis and polymyositis are also frequently restricted to sinovial joints and skeletal muscles, respectively (Bouysset et al. 2005, Briani et al. 2006).

Another problematic point in the current classification system is that many patients present features that overlap two or more of the defined autoimmune diseases. It is not unusual, for example, that a patient with SLE presents isolated features suggestive of systemic sclerosis, such as swollen fingers, Raynaud’s phenomenon, and esophageal dismotility (Furtado et al. 2002). In some cases, there is concomitant full-blown presentation of two or more of these conditions. The current classification system accommodates those cases as overlap syndromes (Rodriguez-Reyna and Alarcon-Segovia 2006). In addition, the association of an organ-specific and a non-organ specific disease is quite frequent. For example, patients with rheumatoid arthritis are frequently affected by thyroid autoimmune diseases (Somers et al. 2006).

However, the most crucial deficiency in the autoimmune disease classification system is the failure to appropriately addressing the large heterogeneity of each nosologic entity. The diagnosis of SLE per se, for example, is not enough to provide an accurate prediction of the prognosis of that particular patient or of when and what kind of treatment should be started. There is a wide

...
suffer no major impact on life style and no major interference with life perspectives. Some other patients with SLE may present serositis, thrombocytopenia, deforming skin involvement, and incapacitating fatigue. These may experience considerable interference with life style and professional and social performance. Finally, some other patients equally diagnosed as SLE may present severe and life-threatening manifestations, such as CNS vasculitis, alveolar hemorrhage or severe class IV glomerulonephritis. These few examples show clearly that it is not enough to say that a given patient has SLE. An accurate nosologic classification system should be able to narrow down the spectrum of manifestations expected for that diagnostic label and, therefore, allow for an accurate prediction of the disease course and the correspondent therapeutic planning for the patient (Fig. 2). Part of the complexity of disease phenotype is determined by non-genetic elements, such as environmental exposure, life style, quality of the medical care, compliance to the treatment, social and cultural level and existing co-morbidity. However, lessons from animal models and from clinical research have pointed that gene polymorphism also plays an important role in the determination of specific autoimmune phenotypes.

Fig. 2 – Unraveling well-defined sub-phenotypes underneath broad-label general syndromes. Different patients with the label of a general syndrome (upper panel), like SLE for example, present specific clinical presentations with peculiar prognostic and therapeutic implications (lower panel).

Should the SLE entity be split into several other nosologic units? Should the SLE label be abandoned? What kind of novel nosologic entities should be defined? Could the same reasoning be appropriate for other autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, polymyositis, and autoimmune liver diseases?

It seems that our contemporary body of knowledge and available technology are clearly not suitable for such a reformulation of the current autoimmune diseases classification system. However, one can always take the neighbor’s experience as a perspective for one’s own development. In fact, the case of the familial periodic fever syndromes, the so-called auto-inflammatory syndromes, may provide a clue to the diagnosis dissection needed for the field of autoimmune diseases.

THE EXAMPLE OF THE AUTO-INFLAMMATORY SYNDROMES

The recent development in the field of the hereditary auto-inflammatory syndromes is quite exciting. For many decades, the Mediterranean familial fever was the only form of hereditary periodic fever syndrome to be clinically and epidemiologically individualized. Over the past 10 years or so, other members of this family of conditions, now designated as auto-inflammatory syndromes, have been defined at the molecular level.

The hereditary periodic fever syndromes are characterized and defined by the following features: recurrent and self-limited episodes of fever and systemic inflammation with no apparent cause; variable involvement of skin, joints, serous membranes and internal organs; the presence of hereditary component; and the development of amyloidosis as a late complication (Grateau 2004). The prototypic and most common auto-inflammatory syndrome is Familial Mediterranean Fever. As suggested by the name, it affects predominantly subjects with descent from the Mediterranean area. It is an autosomal recessive condition caused by mutations in the MEFV gene in region 16p13.3. Heterozygous subjects may present mild traits of the disease. The MEFV gene codes for marenostin, a protein that is able to modulate the effect of caspase 1 on the transcription regulation of IL-1β gene. Mutations in MEFV gene may cause a deficient inhibition of IL-1β expression and therefore induce a pro-inflammatory status (Zaks et al. 2003, Schaner and...
requirements for classification as auto-inflammatory syndromes and their underlying molecular defects have been identified. These include the Cold Induced Auto-inflammatory Syndromes 1 (CIAS-1) (Aróstegui et al. 2004), the TNF Receptor Associated Periodic Syndrome (TRAPS) (Masson et al. 2004, Aganna et al. 2003), and the Hyper-IgD syndrome (Prietsch et al. 2003). A preliminary list of molecular defects and mechanisms of the auto-inflammatory syndromes is depicted in Table II.

Would it be possible to adapt the molecular model of the auto-inflammatory syndromes to the classification of autoimmune diseases? The case of Autoimmune Lymphoproliferative Syndrome (ALPS) is quite compelling. This condition is characterized by adenomegaly, splenomegaly, autoimmune cytopenias, autoantibodies, and several SLE-like traits (reviewed in Worth et al. 2006). It is caused by mutations in genes involved in the Fas-mediated apoptosis pathway. Subtypes of ALPS with subtle clinical differences have been identified according to the specific molecular defect. Type Ia is caused by mutations in the TNFRSF6 gene (Fas - CD95) (reviewed in Worth et al. 2006). Type Ib is caused by mutations in the CASP10 gene (caspase 10); and type 2b is caused by mutations in the CASP8 gene (caspase 8) (Worth et al. 2006). Although ALPS may offer a molecular definition for some cases labeled as SLE, it is clear that the vast majority of SLE patients have no defect in the Fas-mediated apoptosis pathway. However, other molecular mechanisms are long known to be associated with SLE, as is the case for congenital deficiency of early components of the complement system (C1q, C2, and C4) (Worth et al. 2006). Still, these represent a negligible fraction of SLE patients. Nonetheless, these examples are signaling that it may be possible to segregate specific clinical phenotypes within a very heterogeneous syndrome like SLE and to associate relatively homogeneous clinical phenotypes with specific molecular defects. It has become progressively evident that the genetic regulation of autoimmune diseases is extremely complex, and that the establishment of an autoimmune status is conditioned by the interaction of several dozens of alleles. For the last 15 years, an increasing number of gene polymorphisms have been associated with susceptibility or specific clinical features in several autoimmune diseases. In the case of SLE, for example, several possibilities have been identified.
binding lectin, angiotensin converting enzyme, DNase I, among others (Alarcon-Riquelme 2005).

It is relevant for the present issue that the importance of gene polymorphism is not restricted to the determination of disease susceptibility, but it has also been associated with disease phenotype in human and murine SLE (Nolsoe et al. 2005, Qi et al. 2005, Johansson et al. 2005). In that sense, gene polymorphism may indeed contribute to the dissection of a general syndrome like SLE into sub-phenotypes with distinct clinical, prognostic and therapeutic features. However, it is increasingly apparent that several gene polymorphisms must concert interactively to modulate each specific phenotype. Notwithstanding this complexity, it is possible that the most relevant genes involved in the determination of a given autoimmune phenotype would be eventually amenable to simultaneous analysis in some sort of multiplex platform. In fact, the challenge of a simultaneous and integrated analysis of multiple metabolic pathways is hard to be achieved with the standard research methodology. In this respect, the novel and powerful tools provided by large-scale methodological platforms may prove to be helpful.

THE POTENTIAL CONTRIBUTION OF GENOMICS, TRANSCRIPTOMICS AND PROTEOMICS

As opposed to the traditional approaches in biochemistry, microbiology, and immunology, the last two decades have brought large-scale methodologies that allow the simultaneous analysis of thousands of parameters in a single and even in multiple parallel biological specimens. As opposed to the traditional approach of addressing a single or a few analytes, these methodological platforms offer a comprehensive evaluation of hundreds or thousands of parameters that are collectively expressed as specific patterns associated with certain biological conditions. These complex patterns are sometimes referred to as biological signatures. The science of pattern recognition is long known and deals with the ability of identifying an object or situation by the comprehensive appreciation of the whole instead of the details (Bolinger and Ahlers 1975). This kind of ability is responsible for the recognition of a familiar face, voice or landscape in which the overall pattern is more decisive than appreciating the whole instead of the details (Bolin-
assay. The impact of this methodology may be readily recognized by verifying the enormous number of publications on gene polymorphism of a great variety of genes in the last 10 years, as compared with the primary focus on polymorphism of the HLA system in the past decades.

The reverse transcription of sample messenger RNA into complementary DNA (cDNA) has made it possible to analyze the transcriptome, i.e., the gene expression pattern of a given biological sample. It is well appreciated that the full repertoire of genes of a given species is not used in each cell of the organism. In fact, only a certain assembly of genes is expressed in a given cell type and at a given physiologic status. The gene expression pattern of a given cell contributes to its specific phenotype. For instance, erythroid precursors synthesize hemoglobin and neurons synthesize neurotransmitters. As cells move from a physiologic to a pathologic status, the gene expression pattern and the protein expression profile change accordingly. The cDNA microarray technology has taken advantage of the gene expression pattern, to help distinguishing normal from tumoral tissue in lung, breast, stomach and other forms of cancer (Martin 2006, Brennan et al. 2005). Gene expression and protein profile are expected to be also useful in monitoring the therapeutic gene modulation in several conditions (Wulfkuhle et al. 2004). In SLE, microarray analysis of peripheral blood mononuclear cells has allowed the definition of a characteristic expression signature associated with genes regulated by Type I IFN, and this pattern is associated with disease activity (Beltmont and Gibbs 2004). Proteomic analysis of biological samples has been also applied to the detection of several types of cancer (Orstein et al. 2004, Liotta and Petricoin 2006) and to the assessment of the activity status of certain inflammatory diseases (Stone et al. 2005).

These novel tools have readily contributed to the understanding and managing of diseases associated with cancer and simple genetic syndromes. Applications of this methodology are emerging also for the field of autoimmune diseases. The determination of polymorphisms in genes for cytokines, chemokines, cell surface receptors, adhesion molecules, and downstream signaling proteins has been dedicated to this kind of investigation, and several clinical applications are already available.

Several anti-depressants are metabolized by cytochrome P450 (CYP) enzymes in the liver. It has been demonstrated that polymorphism in CYP 2C19 and 2D6 is associated with the pharmacological activity of venlafaxine, amitriptyline, and risperidone (Eichelbaum et al. 2006, van der Weide et al. 2005). Polymorphism in these genes has been shown to influence drastically the metabolic rate and therefore the effectiveness and toxicity of these drugs. Gene polymorphism influence on therapeutics has been also shown to be relevant to several other conditions, such as cancer, osteoporosis, essential hypertension, and dyslipidemias (Rodriguez-Antona and Martin 2006, Schmitz and Langmann 2006).

Pharmacogenomics has been applied also to systemic autoimmune diseases. In fact, this field is complex and has great potential, as can be exemplified by studies carried on in rheumatoid arthritis. Methotrexate (MTX) has been largely used for this disease and has shown to be effective in 46 to 65% of the cases (Bathon et al. 2000). Toxicity of MTX leading to discontinuation of treatment in RA varies from 10 to 30% (Eichelbaum et al. 2006). A large amount of studies has been dedicated to this kind of investigation, and several clinical applications are already available.

A particular application of gene polymorphism studies in the emerging field of pharmacogenetics or pharmaco genetics. This emerging and promising science is committed with the definition of how gene polymorphism may influence the several pharmacological aspects of a certain drug, including pharmacokinetics, pharmacodynamics, and side effects (Marsh and McLeod 2006, Eichelbaum et al. 2006). A large amount of studies has been dedicated to this kind of investigation, and several clinical applications are already available.
TABLE III
Gene polymorphism association with susceptibility and phenotype of autoimmune diseases.

<table>
<thead>
<tr>
<th>Gene and allele</th>
<th>Clinical condition</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-DQ2 &amp; DQ-8</td>
<td>Celiac Disease</td>
<td>Lundin 2003</td>
</tr>
<tr>
<td>PTPN22 1858T</td>
<td>RA, SLE, GD, type 1 DM and JIA</td>
<td>Lee et al. 2007</td>
</tr>
<tr>
<td>DRB1*07 / CTLA-4 49G</td>
<td>Graves Disease</td>
<td>Kula et al 2006</td>
</tr>
<tr>
<td>GSTM1 null genotype</td>
<td>RA</td>
<td>Morinobu et al. 2006</td>
</tr>
<tr>
<td>CTLA-4*G allele</td>
<td>type 1 DM</td>
<td>Kavoura and Ioannidis 2005</td>
</tr>
<tr>
<td>Desmoglein 1 809C allele</td>
<td>Pemphigus foliaceus</td>
<td>Martel al. 2002</td>
</tr>
<tr>
<td>MBL HYPA haplotype</td>
<td>Primary biliary cirrhosis</td>
<td>Matsushita et al. 2001</td>
</tr>
</tbody>
</table>

Association with disease phenotype

<table>
<thead>
<tr>
<th>Gene and allele</th>
<th>Clinical condition</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTLA-4 +49A allele</td>
<td>Extra-glandular Sjögren’s syndrome</td>
<td>Downie-Doyle et al. 2006</td>
</tr>
<tr>
<td>IL4 Receptor V50 allele</td>
<td>Erosive rheumatoid arthritis</td>
<td>Prots et al. 2006</td>
</tr>
<tr>
<td>FCγRIIB (few copies)</td>
<td>Nephritis in SLE</td>
<td>Aitman et al. 2006</td>
</tr>
<tr>
<td>ACE D allele</td>
<td>Macrovascular disease in SSc</td>
<td>Guiducci et al. 2006</td>
</tr>
<tr>
<td>IL-1α –889T allele</td>
<td>Lack of response to cyclophosphamide in SSc</td>
<td>Beretta et al. 2007</td>
</tr>
<tr>
<td>CCR5 59029G allele</td>
<td>Nephropathy in type 1 DM</td>
<td>Mlynski et al. 2005</td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; GD: Grave’s disease; DM: diabetes mellitus; JIA: juvenile idiopathic arthritis; MBL: mannose binding lectin; ACE: angiotensin converting enzyme; SSc: systemic sclerosis.

Methotrexate (MTX) is a cytotoxic agent that interferes with cellular folate metabolism by binding to and inhibiting dihydrofolate reductase (DHFR), which reduces dihydrofolate (DHF) to tetrahydrofolate (THF), and thereby affects the cellular folate pool. MTXPGs also inhibit thymidylate synthase (TYMS), which converts deoxyuridine to deoxythymidylate in the de novo pyrimidine biosynthetic pathway (Dervieux et al. 2004a). Methylene tetrahydrofolate reductase (MTHFR) is the best studied of the genes in the MTX cellular pathway. MTHFR is important in the generation of 5-methyl-THF, which is the methyl donor for the methylation of homocysteine to methionine by methionine synthase (MS). Two non-synonymous SNPs have been extensively studied. The C677T polymorphism is associated with both MTX sensitivity and disease response (Kavvoura and Ioannidis 2005). The T allele of the C677T SNP has been associated with a greater risk of having active RA compared with patients with the TT genotype. The 3435T allele also seemed to confer a protective effect, with patients homozygous for this allele having a less severe form of RA that was more likely to respond to MTX and prednisone (Pawlak et al. 2004). Genetic variations in other members of the ABC family are quite common and shall be explored in the context of RA and MTX treatment.

The methylenetetrahydrofolate reductase (MTHFR) is the best studied of the genes in the MTX cellular pathway. MTHFR is important in the generation of 5-methyl-THF, which is the methyl donor for the methylation of homocysteine to methionine by methionine synthase (MS). SNPs have been reported for several members of the ABC family of transporters, some of which are involved in MTX efflux from the intracellular compartment. A recent study on the ABCB1 gene has found that patients with the 3435CC and 3435CT genotypes had a greater risk of having active RA compared with patients with the 3435TT genotype. The 3435T allele also seemed to confer a protective effect, with patients homozygous for this allele having a less severe form of RA that was more likely to respond to MTX and prednisone (Pawlak et al. 2004). Genetic variations in other members of the ABC family are quite common and shall be explored in the context of RA and MTX treatment.
associated with homocystein plasma concentration and seems to be associated with MTX toxicity, especially with hepatotoxicity. On the other hand, the A1298C polymorphism seems to have no effect on MTX toxicity, but seems to be associated with MTX efficacy in RA patients (Uran et al. 2002).

Thymidilate synthase (TYMS) is a key enzyme in the de novo thymidylate synthesis (conversion of dUMP into dTMP). TYMS is inhibited directly by MTXPGs and indirectly by the folate cofactor depletion induced by MTX. Two relevant TYMS polymorphisms have been studied with respect to MTX in RA patients. A polymorphic tandem repeat sequence in the 5'-untranslated region (5'-UTR) correlates with TYMS mRNA expression. Patients homozygous for the triple repeat allele (TSER*3/*3) have higher TYMS mRNA expression than those homozygous for a double repeat allele (TSER*2/*2). Another relevant polymorphism consists of a 6-bp deletion of the sequence TTAAAG at nucleotide 1494 in the 3'-UTR (3'-UTR 6-bp deletion). Apparently the 3'-UTR deletion is associated with decreased TYMS mRNA stability and expression. Preliminary evidence suggests that the TSER*3/*3 polymorphism (increased TYMS expression) lowered MTX efficacy and the 3'-UTR 6-bp deletion (decreased TYMS expression) made RA patients more sensitive to MTX (Kumagai et al. 2003).

Several other genes may affect MTX efficacy and toxicity, including AMP-activated protein kinase activator (AICAR), transformylase, γ-glutamyl hydrolase (GGH), dihydrofolate reductase (DHFR), methionine synthase (MS), methionine synthase reductase (MTRR) and serine hydroxymethyltransferase (SHMT). Eventually, the concomitant analysis of the polymorphism in several of these genes will provide an appropriate estimate of the expected therapeutic effect and toxicity of MTX in a given RA patient (Dervieux et al. 2004b).

Tumor necrosis factor (TNF) antagonists have been shown to be rather effective therapeutic alternative for some patients with RA, Crohn’s disease, psoriatic arthritis and ankylosing spondylitis. However, only up to 60% of the patients will present a satisfactory response to anti-TNF therapy. There is a functional bi-allelic polymorphism in the TNF-α gene A-308G, in which the A allele is associated with greater expression of the TNF gene. This trend has been clearly announced as the Individualized Therapeutics approach. Once the molecular imbalance is defined and the appropriate therapeutics is devised, the physician will probably have the same diagnosis as today. In contrast, the vague diagnosis of SLE may change drastically. It may happen that we will not even talk of SLE in the future. Specific immunologic imbalances conditioned by peculiar sets of gene polymorphisms and characterized by defined patterns of immune mediators expression may be identified within the broad family of patients nowadays diagnosed as SLE. Each one of these molecularly defined SLE subsets shall be associated with a peculiar clinical picture and prognosis. Accordingly, the appropriate therapy will be individualized for each one of these novel molecular-defined nosologic entities. Eventually, it is possible that efforts will be addressed to the individual molecular imbalances of each patient as opposed to the current efforts to classify patients into pre-defined general nosologic categories. This trend has been clearly announced as the Individualized Medicine.

The perspectives provided by the novel available technologies appear to promise a real revolution not only in diagnostic procedures, but also in the current pattern for Medicine itself. The nosologic classification as we know it today may be totally reshaped in some areas of Medicine. Some fields will not undergo radical changes. For example, a patient with inguinal hernia will probably have the same diagnosis as today. In contrast, the vague diagnosis of SLE may change drastically. It may happen that we will not even talk of SLE in the future. Specific immunologic imbalances conditioned by peculiar sets of gene polymorphisms and characterized by defined patterns of immune mediators expression may be identified within the broad family of patients nowadays diagnosed as SLE. Each one of these molecularly defined SLE subsets shall be associated with a peculiar clinical picture and prognosis. Accordingly, the appropriate therapy will be individualized for each one of these novel molecular-defined nosologic entities. Eventually, it is possible that efforts will be addressed to the individual molecular imbalances of each patient as opposed to the current efforts to classify patients into pre-defined general nosologic categories. This trend has been clearly announced as the Individualized Medicine.

On the top of that, pharmacogenetics will provide an additional degree of individualization for the patients. Once the molecular imbalance is defined and the appropriate therapeutics is devised, the physician will provide.
TABLE IV
Fiction patient in year 2097.

- Disequilibrium Th1/Th2 in peripheral blood → 65%
- Depressed proportion of Treg in peripheral blood → 0.5%
- DRB1 gene polymorphism → presence of single copy of *0404 allele
- MBL gene heterozigosity → presence of alleles A and D
- TNF-α gene promoter polymorphism at –308 → allele –308A in double copy
- Homozygosity for allele 131R in FcγRII gene
- Protein tyrosine phosphatase non-receptor 22 (PTPN22) → single copy of 1858T allele
- Decreased Thymus Recent-Emigrant T cells → 15,4678 TREC copies/μg CD4⁺DNA
- Hyperexpression of IL-17, IL-2 and osteoprotegerin
- Acceleration in IFN-γ-induced gene activation sequence in macrophages

for some applications it is already feasible to assess how polymorphism of individual genes influences the therapeutic response to certain drugs. It is quite possible that the molecular definition of disease condition and therapeutics on an individual basis will occur concomitantly in an interactive fashion. This trend has been termed Theranostics and may dominate the management of patients in the future (Picard and Bergeron 2002, Jain 2002).

MEDICINE IN YEAR 2097

It seems not risky to forecast that Medicine will change drastically in the coming decades. Many of the clinical entities, diagnostic procedures, and therapeutic options of today shall disappear. Novel paradigms, the emerging technology, and the evolving clinical practice shall re-shape each other towards a more individualized Medicine. In a provocative scenario, one can foresee the clinical workout of a patient in year 2097 (Table IV). This may cause wonder and skepticism to some of us nowadays in the same way that our current medical approach would have caused if shown to a 1597’s physician (Table I). This historical perspective is reassuring in that it lends credibility to the viability of an accomplishing future for Medicine. However, a word of caution must be said with respect to the economical impact of the current and evolving health care. The constant progress in medical diagnosis and treatment has generated genuine cost inflation in the health care system coming economically feasible in order to thrive.

RESUMO

O homem tem buscado sucessivas abordagens para o entendimento e manejo das doenças. Partindo de conceitos sobrenaturais e procedimentos místicos, uma abordagem científica vigorosa venceu com base em disciplinas fundamentais como a anatomia, microbiologia, bioquímica, fisiologia, imunologia, patologia e farmacologia. O conhecimento integrado resultante contribuiu para a atual classificação das doenças e a forma com que a Medicina atual é praticada. Apesar deste conside-rável progresso, esta abordagem é insuficiente quando se trata de condições inflamatórias sistêmicas, como o lúpus eritematoso sistêmico, que abrange condições variando de formas brandas e pauci-sintomáticas até condições rapidamente fatais. O tratamento dessas condições é frequentemente insuficiente e novas abordagens são necessárias para progresso adicional nessas áreas da Medicina. Um avanço recente foi obtido no que tange às síndromes auto-inflamatórias hereditárias, nas quais a dissecação molecular dos defeitos gênicos subjacentes forneceu direcionamento para terapia orientada a alvos moleculares específicos. Esta abordagem é passível de aplicação às doenças auto-imunes sistêmicas com a compreensão de essas condições podem ser conseqüência da interação de estímulos ambientais específicos e uma gama de vários polimorfismos gênicos interconectados. No escopo dessa transformação, a aplicação dos princípios de farmacogenética poderá contribuir para o progressivo desenvolvimento de uma Medicina personalizada vigorosa.
REFERENCES


BARCELLOS KS, NONOGAKI S, ENOKIHARA MM, TEIXEIRA MS AND ANDRADE LE. 2007. Differential Expression of Ro(SSA) 60 kDa and La(SSB), but not Ro(SSA) 52 kDa, mRNA and Protein in Minor Salivary Glands from Patients with Primary Sjögren’s Syndrome. J Rheumatol 34: 1283–1292.


NOSOE RL, KELLY JA, POICT F, MOSER KL, KRIS

LUIS E.C. ANDRADE

An Acad Bras Cienc (2009)
PERSPECTIVES IN DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNITY


